Characterization of Polymorphisms Associated with Multidrug-Resistant Tuberculosis by Whole Genomic Sequencing: A Preliminary Report from Mexico
Por:
Zenteno-Cuevas R, Fernandez E, Viveros D, Madrazo-Moya CF, Cancino-Muñoz I, Comas I, Gonzalez-Covarrubias V, Barbosa-Amezcua M and Cuevas-Cordoba B
Publicada:
1 jul 2020
Ahead of Print:
1 dic 2019
Resumen:
Whole genome sequencing (WGS) has been proposed as a tool for the diagnosis of drug resistance in tuberculosis (TB); however, there have been few studies on its effectiveness in countries with significantly high drug resistance rates. This study therefore aimed to evaluate the effectiveness of WGS to identify mutations related to drug resistance in TB isolates from an endemic region of Mexico. The results showed that, of 35 multidrug-resistant isolates analyzed, the values of congruence found between the phenotypic drug susceptibility testing and polymorphisms were 94% for isoniazid, 97% for rifampicin, 90% for ethambutol, and 82% for pyrazinamide. It was also possible to identify eight isolates as potential pre-extensive drug resistant (XDR) and one as XDR. Twenty nine isolates were classified within L4 and two transmission clusters were identified. The results show the potential utility of WGS for predicting resistance against first- and second-line drugs, as well as providing a phylogenetic characterization of TB drug-resistant isolates circulating in Mexico.
Filiaciones:
Zenteno-Cuevas R:
Instituto de Salud Pública, Universidad Veracruzana, Veracruz, México
Programa de Maestría en Ciencias de la Salud, Instituto de Ciencias de la Salud, Universidad Veracruzana, Veracruz, México
Programa de Doctorado en Ciencias Biomédicas, Centro de Investigaciones Biomédicas, Universidad Veracruzana, Veracruz, México
Fernandez E:
Instituto de Salud Pública, Universidad Veracruzana, Veracruz, México
Programa de Maestría en Ciencias de la Salud, Instituto de Ciencias de la Salud, Universidad Veracruzana, Veracruz, México
Viveros D:
Programa de Doctorado en Ciencias Biomédicas, Centro de Investigaciones Biomédicas, Universidad Veracruzana, Veracruz, México
Madrazo-Moya CF:
Instituto de Salud Pública, Universidad Veracruzana, Veracruz, México
Cancino-Muñoz I:
Biomedicine Institute of Valencia IBV-CSIC, Valencia, Spain
CIBER in Epidemiology and Public Health, Valencia, Spain
:
Biomedicine Institute of Valencia IBV-CSIC, Valencia, Spain
CIBER in Epidemiology and Public Health, Valencia, Spain
Gonzalez-Covarrubias V:
Laboratorio de Farmacogenómica, Instituto Nacional de Medicina Genómica, Ciudad de México, México
Barbosa-Amezcua M:
Laboratorio de Farmacogenómica, Instituto Nacional de Medicina Genómica, Ciudad de México, México
Cuevas-Cordoba B:
Laboratorio de Farmacogenómica, Instituto Nacional de Medicina Genómica, Ciudad de México, México
|